RxDoctor Payments Data

Michelle Maier, NP

Family · Bismarck, NDNPI 1831243005

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,690 of the $4,007 with a category attached, or 67.1%. AbbVie accounts for 91.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $3,271 and has fallen 93.2% since, to $223 in 2025. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,007in general payments, 2019–2025

Across 66 payments — averaging $60.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Pfizer$84
  • Exact Sciences$77
  • Astellas Pharma US Inc$39
  • Takeda Pharmaceuticals U.S.A., Inc.$38
  • Kerr Corporation$21
  • plus $76 from 4 others

What the payments were for

  • Speaking & faculty fees$2,69067%
  • Grants$211%
  • Food & beverage$1,29732%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,007 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$21,583
Medicare patients
98
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium45$2,341
Levothyroxine Sodium132$1,748
Venlafaxine Hcl ErVenlafaxine Hcl47$784
Bupropion XlBupropion Hcl34$758
ValacyclovirValacyclovir Hcl18$690
Rosuvastatin Calcium60$647
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$601
FenofibrateFenofibrate Nanocrystallized15$597
Metoprolol Succinate42$525
Losartan Potassium47$504
Omeprazole47$469
Irbesartan14$429
Liothyronine Sodium18$428
Pantoprazole Sodium17$358
Sertraline Hcl13$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$3,672$2,34145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.

Other family in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →